Innate Therapeutics Receives Funding For Clinical Trial Of Progressive Multiple Sclerosis Therapeutic
Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
Click here to read more
MS could be reversed with existing allergy drug
16 hours ago